Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Prasterone (Primary)
- Indications Decreased libido
- Focus Therapeutic Use
- Acronyms Second Study
- Sponsors Endoceutics
- 15 Nov 2019 Planned initiation date changed from 1 Oct 2019 to 13 Nov 2018.
- 15 Nov 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 01 Feb 2019 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.